Grifols, S.A. $GRFS Shares Purchased by Flat Footed LLC

Flat Footed LLC grew its position in Grifols, S.A. (NASDAQ:GRFS) by 26.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 1,372,394 shares of the biotechnology company’s stock after buying an additional 287,867 shares during the period. Grifols makes up approximately 1.2% of Flat Footed LLC’s investment portfolio, making the stock its 8th largest position. Flat Footed LLC’s holdings in Grifols were worth $11,007,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Bank of Montreal Can boosted its position in shares of Grifols by 3,205.1% during the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after buying an additional 2,922,540 shares during the period. Arrowstreet Capital Limited Partnership increased its position in Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after acquiring an additional 2,221,633 shares during the period. Norges Bank acquired a new stake in Grifols in the 4th quarter valued at approximately $18,139,000. Brandes Investment Partners LP raised its stake in Grifols by 6.3% during the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock valued at $289,422,000 after acquiring an additional 1,838,727 shares in the last quarter. Finally, Barclays PLC boosted its position in Grifols by 132.6% during the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after acquiring an additional 1,387,783 shares during the period.

Grifols Price Performance

Shares of GRFS stock opened at $7.58 on Monday. Grifols, S.A. has a 1 year low of $6.96 and a 1 year high of $11.14. The stock has a market cap of $5.16 billion, a PE ratio of 39.89, a price-to-earnings-growth ratio of 0.29 and a beta of 0.67. The business’s fifty day moving average is $7.51 and its 200-day moving average is $8.21. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47.

Grifols Announces Dividend

The company also recently announced a special dividend, which was paid on Thursday, July 9th. Investors of record on Thursday, July 2nd were paid a dividend of $0.0945 per share. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s dividend payout ratio (DPR) is currently 121.05%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on GRFS shares. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings downgraded shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Finally, Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Grifols has a consensus rating of “Reduce” and a consensus target price of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.